Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Riedl, JM; Posch, F; Bezan, A; Szkandera, J; Smolle, MA; Winder, T; Rossmann, CH; Schaberl-Moser, R; Pichler, M; Stotz, M; Stöger, H; Gerger, A.
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
BMC Cancer. 2017; 17(1):415-415
Doi: 10.1186/s12885-017-3392-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Riedl Jakob
- Co-Autor*innen der Med Uni Graz
- Gerger Armin
- Pichler Martin
- Posch Florian
- Schaberl-Moser Renate
- Smolle Maria Anna
- Stöger Herbert
- Stotz Michael
- Szkandera Joanna
- Terbuch Angelika
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Venous thromoboembolism (VTE) is a frequent and burdensome complication of metastatic colorectal cancer (CRC). However, the epidemiology of VTE in patients with localized CRC after surgery in curative intent is incompletely understood. In this single-center observational cohort study, we investigate patterns of VTE risk in localized CRC, and define its relationship with baseline risk factors, adjuvant chemotherapy and CRC recurrence. Five-hundred-sixteen patients with stage II/III CRC were included retrospectively at the time of surgery, and followed until the occurrence of VTE, CRC recurrence, or death (median age = 65.1 years, stage II and III: n = 151 (29.5%), n = 361 (70.5%); adjCTX: n = 339 (65.7%)). During a median follow-up of 2.7 years, 15 VTEs (2.7%) and 116 recurrences (22.5%) occurred, and 46 patients (8.9%) died. Six-month, 1-year, and 5-year VTE risks were 1.6%, 2.0% and 3.2%, respectively. In competing risk time-to-VTE regression, adjCTX was not associated with an increased risk of VTE (Subdistribution hazard ratio = 0.98, 95% CI:0.33-2.88, p = 0.97). The occurrence of disease recurrence strongly increased the risk of VTE (Multi-state model: Transition hazard ratio (THR) = 13.03, 95% CI:4.39-38.74, p < 0.0001)). Conversely, the onset of VTE did not predict for recurrence (THR = 1.95, 95% CI: 0.62-6.16, p = 0.25). VTE risk is very low in localized CRC and does not appear to be increased by adjuvant chemotherapy. Thus, primary thromboprophylaxis is unlikely to result in clinical benefit in this population. The strongest determinant of VTE risk appears to be disease recurrence.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Chemotherapy, Adjuvant -
- Cohort Studies -
- Colorectal Neoplasms - complications
- Colorectal Neoplasms - drug therapy
- Colorectal Neoplasms - mortality
- Colorectal Neoplasms - pathology
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Middle Aged -
- Neoplasm Recurrence, Local -
- Neoplasm Staging -
- Prognosis -
- Risk -
- Venous Thromboembolism - epidemiology
- Venous Thromboembolism - etiology
- Venous Thromboembolism - mortality
- Young Adult -
- Find related publications in this database (Keywords)
- Venous thromboembolism
- Thrombosis
- Colorectal cancer
- Recurrence
- Adjuvant chemotherapy